{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.64","upperLimit":"5.49","value":"3.55"},{"groupId":"OG001","lowerLimit":"0.95","upperLimit":"42.07","value":"3.55"},{"groupId":"OG002","lowerLimit":"1.51","upperLimit":"14.77","value":"3.52"},{"groupId":"OG003","lowerLimit":"1.74","upperLimit":"4.21","value":"3.05"},{"groupId":"OG004","lowerLimit":"1.58","upperLimit":"20.53","value":"1.84"},{"groupId":"OG005","lowerLimit":"1.64","upperLimit":"14.77","value":"2.89"},{"groupId":"OG006","lowerLimit":"1.18","upperLimit":"3.68","value":"2.36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"9"}],"units":"Participants"}],"description":"Time from the first dose of CTX-471 to disease progression (as assessed by Response Evaluation Criteria in Solid Tumours guideline version 1.1) or death","dispersionType":"Full Range","groups":[{"description":"0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG000","title":"CTX-471 Monotherapy 0.1 mg/kg"},{"description":"0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG001","title":"CTX-471 Monotherapy 0.3 mg/kg"},{"description":"0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG002","title":"CTX-471 Monotherapy 0.6 mg/kg"},{"description":"1.2 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG003","title":"CTX-471 Monotherapy 1.2 mg/kg"},{"description":"0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG004","title":"CTX-471 Combination 0.1 mg/kg"},{"description":"0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG005","title":"CTX-471 Combination 0.3 mg/kg"},{"description":"0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG006","title":"CTX-471 Combination 0.6 mg/kg"}],"paramType":"MEDIAN","populationDescription":"Response Evaluable Analysis Set: all patients with measurable disease before treatment who received CTX-471 (and pembrolizumab in combination arms) and had at least 1 post-treatment response assessment or discontinued treatment due to progression of disease progression within 8 weeks after first dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From the first dose of CTX-471 to progression of disease or death","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}